Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 526–550 of 586 studies · free to read · tagged Health Equity (page 22 of 24) · 32,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Low income and vulnerability to arterial hypertension were the primary contributors to AD/ADRD disparities, with cerebrovascular diseases and depression as notable secondary predictors. 5 key findings →

Evidence: low

Summary statistics were obtained for sociodemographic and chronic diseases by using cross-tabulation analysis and comparing the county respondents with proportion tests. 5 key findings →

Evidence: low

Factors influencing adults' willingness to be screened for dementia risk

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Alzheimer s & Dementia 2024-12-01

Although White and non-White participants were both willing to test (∼77%), non-White participants were approximately four times more likely to test only if their results were not shared with their medical provider/insurer. 5 key findings →

Evidence: low

Our study highlights the potential of Decipher‐AI for screening undiagnosed cognitive impairment in primary care. 3 key findings →

Evidence: low

ADI was positively associated with blood pressure and cardiometabolic index (CMI), and negatively associated with global and Preclinical Alzheimer's Cognitive Composite (PACC5) scores, in cognitively unimpaired (CU) individuals. 4 key findings →

Evidence: low

MDD prevalence was consistently higher among women than men across all regions and age groups, ranging from 4.42%-5.11% in women versus 2.87%-3.41% in men. 5 key findings →

Evidence: low

SDOH are potentially modifiable factors, therefore, a deeper understanding of their effects on ADRD can inform future interventions aimed at reducing ADRD prevalence and disparities. 5 key findings →

Evidence: low

In highly segregated counties, Black older adults with elevated CVD demonstrated worse memory than those with lower CVD; in less segregated counties, memory levels did not differ by CVD. 4 key findings →

Evidence: low

In 2023, US life expectancy reached 78.5 years and healthy life expectancy 64.5 years, both still below prepandemic 2019 levels, with a persistent 13-14-year gap between life expectancy and healthy life expectancy. 5 key findings →

Evidence: low

Development of a Rural and Remote Dementia Training Framework

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Australian Journal of Rural Health 2025-11-01

Synthesis of the results identified three overarching key principles and seven actionable practices for consideration when designing or delivering dementia education to the rural and remote health and aged care workforce. 2 key findings →

Design: clinical trial Evidence: low

Keeping current with the burden and risk factors of Alzheimer disease and other dementias (ADOD) from global to national levels is critical for healthcare planning, prevention strategies, and the allocation of resources. 2 key findings →

Evidence: low

Among 15,346 White, 829 Latino, 637 Black/African American, and 321 Asian individuals, 51% were female, mean age was 75.7 years, 535 (3.8%) resided in ADI 91 to 100 decile, and 61.6% were amyloid PET positive. 3 key findings →

Evidence: low

Based on the stakeholder responses from fifteen providers and twenty community members, there was strong consensus in the need for local brain health services. 5 key findings →

Design: clinical trial Evidence: low

Community-based participatory research (CBPR) offers effective, flexible approaches well suited to conduct health research with underrepresented populations that can be tailored to unique social, cultural, and geographic contexts. 5 key findings →

Evidence: low

Successfully embedding technology into long-term care settings requires intentional, evidence-based community engagement strategies that address the unique needs of providers, caregivers, and persons living with dementia. 1 key finding →

Participants: 17 Evidence: low

Thirty thousand three hundred and ninety-eight deaths attributable to dementia as the underlying or related cause (multiple causes) were reported during 2015-2019. 5 key findings →

Evidence: low

These findings suggest that caregivers living in rural regions may depend more on informal support for meeting basic care needs of their relative living with dementia. 3 key findings →

Participants: 163 Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated